58.21

0.14% -0.08

Royalty Pharma Plc (RPRX)

Overview News Price History Option Chain Financials Discussions Forecast Dividend History

Royalty Pharma Plc stock is traded at $58.21, with a volume of 1.87M. It is down -0.14% in the last 24 hours and down -6.22% over the past month. Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Previous Close:

$58.29

Open:

$58.5

24h Volume:

1.87M

Relative Volume:

0.63

Market Cap:

$25.92B

Revenue:

$2.44B

Net Income/Loss:

$1.36B

P/E Ratio:

30.49

EPS:

1.9093

Net Cash Flow:

$574.14M

1W Performance:

-0.34%

1M Performance:

-6.22%

6M Performance:

+23.77%

1Y Performance:

+66.79%

1-Day Range:

$57.68

$58.50

1-Week Range:

$57.63

$59.06

52-Week Range:

$34.63

$64.38

Royalty Pharma Plc Stock (RPRX) Company Profile

Name

Royalty Pharma Plc

Sector

Healthcare (1067)

Industry

Biotechnology (595)

Phone

(212) 883-0200

Address

110 EAST 59TH STREET, NEW YORK, NY

Employee

100

Twitter

Next Earnings Date

2026-11-04

Latest SEC Filings

RPRX's Discussions on Twitter

Compare RPRX vs VRTX, REGN, MRNA, ARGX, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RPRX Royalty Pharma Plc	58.21	25.92B	2.44B	1.36B	574.14M	1.9093
VRTX Vertex Pharmaceuticals Inc	526.19	133.37B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	788.04	81.13B	14.92B	4.42B	3.79B	41.04
MRNA Moderna Inc	198.88	79.40B	2.23B	-3.19B	-1.60B	-8.1462
ARGX Argen X Se Adr	959.49	60.03B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	204.97	43.93B	742.00K	-1.37B	-1.07B	-7.0731

Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-30-26	Upgrade	UBS	Neutral → Buy
Sep-30-25	Initiated	Goldman	Buy
May-16-25	Initiated	Morgan Stanley	Overweight
Jun-03-24	Downgrade	UBS	Buy → Neutral
Jun-14-22	Resumed	UBS	Buy
May-13-22	Initiated	Scotiabank	Sector Outperform
Apr-27-22	Initiated	Goldman	Buy
Apr-14-22	Upgrade	JP Morgan	Neutral → Overweight
Apr-06-22	Resumed	Morgan Stanley	Overweight
Oct-29-21	Upgrade	Citigroup	Neutral → Buy
Jul-30-21	Initiated	Tigress Financial	Buy
Nov-09-20	Upgrade	UBS	Neutral → Buy
Jul-14-20	Initiated	Evercore ISI	In-line
Jul-13-20	Initiated	BofA Securities	Buy
Jul-13-20	Initiated	Citigroup	Neutral
Jul-13-20	Initiated	Cowen	Outperform
Jul-13-20	Initiated	Goldman	Neutral
Jul-13-20	Initiated	JP Morgan	Neutral
Jul-13-20	Initiated	Morgan Stanley	Equal-Weight
Jul-13-20	Initiated	SunTrust	Buy
Jul-13-20	Initiated	UBS	Neutral

View All

Royalty Pharma Plc Stock (RPRX) Latest News

04:17 AM

Form 144 Royalty Pharma PLC For: 27 September By Investing.com - Investing.com India

04:17 AM

Sep 26, 2026

Royalty Pharma (NASDAQ:RPRX) Rating Lowered to Buy at Wall Street Zen - MarketBeat

Sep 26, 2026

Sep 25, 2026

Form 4 Royalty Pharma Plc For: 25 September By Investing.com - Investing.com Canada

Sep 25, 2026

Royalty Pharma EVP Christopher Hite sells $5.85m in shares - Investing.com

Sep 25, 2026